From:
$50.00
Prescription required
Ganirelix Acetate (Antagon): Uses, Dosage, Side Effects, and More
Reviewed by:
From:
$50.00
Prescription required
Ganirelix acetate is an injectable, synthetic decapeptide classified as a competitive gonadotropin-releasing hormone (GnRH) antagonist. It is used as a core component of assisted reproductive technologies (ART), such as in vitro fertilization (IVF), to prevent premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH). It works by competitively blocking pituitary GnRH receptors, causing an immediate and reversible suppression of gonadotropin secretion without the initial flare effect associated with older GnRH agonists. Ganirelix is administered via subcutaneous injection during the mid-to-late follicular phase of a stimulated fertility cycle.
Your Prescription
Ready to Fill
Drug Facts
Generic name
Ganirelix Acetate
Brand names
Antagon, Orgalutran
Drug type
Gonadotropin-Releasing Hormone (GnRH) Antagonist
Controlled substance
No
Dosage forms
Prefilled, single-dose glass syringes (250 mcg / 0.5 mL)
Typical dosage
250 mcg subcutaneously once daily, initiated on approximately Day 7 or Day 8 of the stimulated cycle (or once the lead follicle reaches ≥14 mm), and continued until the day of trigger administration; average duration 4 to 6 consecutive days.
Basics
What is Ganirelix Acetate?
Ganirelix acetate is an injectable, synthetic decapeptide classified as a competitive gonadotropin-releasing hormone (GnRH) antagonist. It is indicated for inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) as a core component of assisted reproductive technologies (ART), such as in vitro fertilization (IVF).
During a typical fertility cycle, exogenous follicle-stimulating hormone (FSH) is administered to stimulate the growth of multiple ovarian follicles. As these follicles mature, they secrete high levels of estradiol, which can inadvertently trigger an early, premature LH surge. A premature surge causes the follicles to luteinize and release eggs too early, resulting in the harvesting of immature oocytes or a canceled cycle. Ganirelix provides immediate, predictable chemical control over the pituitary gland, preventing premature ovulation until the oocytes are of adequate size for retrieval.
Indications
What is Ganirelix Acetate used for?
Ganirelix acetate is indicated for the prevention of premature LH surges in women undergoing controlled ovarian hyperstimulation as part of assisted reproductive technology procedures such as in vitro fertilization (IVF).
Mechanism
How does Ganirelix Acetate work?
Pharmacodynamics
The pulsatile release of endogenous GnRH from the hypothalamus normally stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from pituitary gonadotroph cells.
Ganirelix acetate functions as a potent competitive antagonist at the pituitary GnRH receptor sites. By binding to these receptors with high affinity, it physically blocks endogenous GnRH from triggering its downstream cellular signaling pathway. This results in an immediate, profound, and reversible suppression of gonadotropin secretion.
The suppression of pituitary LH secretion by ganirelix is significantly more pronounced than that of FSH. Unlike older GnRH agonists (such as leuprolide), which initially cause a transient surge or flare of LH and FSH before downregulating receptors over several weeks, ganirelix exerts an immediate antagonistic effect with no initial gonadotropin release. Upon discontinuation of the drug, pituitary LH and FSH levels fully recover within 48 hours.
Pharmacokinetics
- Absorption: Ganirelix acetate is rapidly absorbed following a single subcutaneous injection, reaching its peak plasma concentration (Tmax) approximately 1.1 hours post-dose. The mean absolute bioavailability is exceptionally high at 91.1%. Steady-state serum concentrations are achieved after 3 days of continuous, once-daily dosing.
- Distribution: Following administration, ganirelix distributes adequately into extracellular fluids, exhibiting a steady-state volume of distribution of approximately 43.7 liters. In vitro plasma protein binding is roughly 81.9%.
- Metabolism: Ganirelix is the primary circulating compound found in plasma up to 4 hours post-injection. It undergoes minimal hepatic metabolism into minor peptide fragments.
- Elimination: The drug exhibits a terminal elimination half-life of approximately 12.8 hours after a single dose and approximately 16.2 hours after multiple daily doses. Clearance is predominantly non-renal, with approximately 75.1% of the radiolabeled dose recovered in the feces and 22.1% excreted in the urine over 288 hours.
Dosage
Ganirelix Acetate Dosages & Administration
Standard Clinical Dosing Protocol
- Controlled Ovarian Hyperstimulation Program: Treatment with exogenous gonadotropins (such as recombinant FSH) is typically initiated on Day 2 or Day 3 of the patient’s menstrual cycle.
- Ganirelix Initiation: Ganirelix acetate 250 mcg subcutaneously once daily is introduced during the mid-to-late follicular phase of the cycle. This typically occurs on Day 7 or Day 8 of the cycle (or once the lead ovarian follicle reaches a diameter of 14 millimeters or greater on ultrasound monitoring).
- Duration of Use: Daily treatment with ganirelix must be continued until the day of administration of human chorionic gonadotropin (hCG) or a GnRH agonist trigger, which induces final oocyte maturation before egg retrieval. The average duration of ganirelix therapy is 4 to 6 consecutive days.
Strict Administration Guidelines
- Subcutaneous Administration Only: Ganirelix is formulated strictly for subcutaneous injection. The recommended injection sites are the abdomen (in a semi-circle around the navel) or the upper thigh.
- Technique: The injection site should be rotated daily to minimize localized tissue irritation. The skin must be cleaned, pinched upward between the thumb and forefinger, and the needle inserted at a 45-degree to 90-degree angle. The plunger should be depressed completely, and the single-dose prefilled syringe discarded immediately into a sharps container.
Get The Right Dose For Less
Why pay retail prices for the same medication?
At Invictus, we source directly from trusted, FDA-approved manufacturers to keep your costs low without sacrificing quality. Whether you need a one-time fill or regular refills, our transparent pricing makes it easy to save every day.
Side Effects
Ganirelix Acetate Side Effects and Risks
Hypersensitivity and Severe Allergic Reactions
Cases of acute hypersensitivity reactions, including generalized urticaria, pruritus, facial angioedema, and life-threatening anaphylaxis (including anaphylactic shock), have been documented during post-marketing surveillance. These allergic events can manifest as early as the very first dose. If a systemic allergic reaction is suspected, ganirelix must be discontinued immediately, and emergency supportive therapies administered. Clinicians should exercise extreme caution when treating women with signs, symptoms, or a known clinical history of active, severe allergic conditions.
Natural Rubber / Latex Warning
The needle shield of certain manufacturers’ prefilled ganirelix syringes is constructed utilizing rigid components containing dry natural rubber or latex derivatives. This latex shield comes into direct physical contact with the product needle. Therefore, ganirelix syringes packaged with these shields are strictly contraindicated in individuals with a known or suspected history of severe latex allergy, as accidental exposure can trigger localized contact dermatitis or systemic anaphylaxis. Alternative latex-free syringe presentations must be confirmed before dispensing.
Ovarian Hyperstimulation Syndrome (OHSS)
OHSS is a serious, potentially life-threatening medical complication resulting from aggressive controlled ovarian hyperstimulation. While ganirelix is used to regulate the cycle, the underlying stimulation of multiple follicles can cause rapid fluid shifts.
- Clinical Manifestations: Severe OHSS causes a dramatic increase in vascular permeability, leading to rapid fluid accumulation in the peritoneal, pleural, and pericardial cavities. Symptoms include severe abdominal pain, notable abdominal distension, rapid weight gain (greater than 3 pounds in 24 hours), persistent nausea, vomiting, severe oliguria (low urine output), and dyspnea.
- Complications: Can progress rapidly to acute renal failure, hypovolemic shock, pleural effusion, and thromboembolic events. Patients exhibiting warning signs must be closely monitored with blood chemistry panels, hematocrit monitoring, and pelvic ultrasounds; fluid restriction and supportive clinical therapies should be initiated.
Embryo-Fetal Toxicity
Ganirelix acetate is indicated solely for fertility induction and is strictly contraindicated during an active pregnancy. Animal reproductive toxicity studies evaluating ganirelix during organogenesis demonstrated a statistically significant increase in the incidence of complete litter resorption. Before initiating the first dose of ganirelix at the mid-follicular phase, the presence of an underlying pregnancy must be definitively excluded via serum or urinary beta-hCG testing.
Common Adverse Reactions
The most frequent side effects documented in controlled reproductive clinical trials include:
- Local injection site reactions (transient erythema, swelling, bruising, and localized stinging, which typically resolve spontaneously within 4 hours)
- Gynecological abdominal pain and pelvic discomfort
- Headache
- Ovarian Hyperstimulation Syndrome (OHSS)
- Vaginal bleeding or spotting
- Nausea
Interactions
Ganirelix Acetate Interactions
Formal in vivo drug-drug interaction studies have not been conducted with ganirelix acetate. Because ganirelix suppresses the secretion of pituitary gonadotropins, it interacts dynamically with the concurrent administration of exogenous gonadotropins (FSH/LH). The dosage of exogenous gonadotropins must be adjusted dynamically based on serial transvaginal ultrasound measurements of follicular growth and serum estradiol levels to balance adequate oocyte maturation with the prevention of hyperstimulation.
Contraindications
Additional Considerations
Renal and Hepatic Impairment
The pharmacokinetic and metabolic behavior of ganirelix acetate has not been formally evaluated in patients with documented renal or hepatic insufficiency. Because a significant portion of the drug undergoes non-renal clearance via fecal and biliary routes, structural hepatic impairment could theoretically extend the drug’s half-life and increase systemic exposure.
Lactation
It is unknown whether ganirelix acetate is excreted into human breast milk. Because ganirelix is indicated exclusively for ovulation induction before conception, its clinical use is not intended during lactation. Use is not recommended in breastfeeding individuals.
Ready to Start Saving?
No one should overpay for safe, effective medication. By cutting out middlemen and working directly with trusted, FDA-approved manufacturers, Invictus offers the same high-quality medicines you’d find at big retail pharmacies—at a fraction of the price.
Whether you choose brand-name or generic, we’ll deliver it quickly, affordably, and right to your door. Maybe that’s why most patients who switch to Invictus never look back.
Frequently Asked Questions (FAQs)
Didn’t see the answers you’re looking for in this article? Check out this comprehensive FAQ for more details.
Administration & Dosage
Ganirelix is administered as a subcutaneous injection into the fatty tissue just beneath the skin, typically in the lower abdomen below the navel. Before injecting, allow the prefilled syringe to reach room temperature, clean the injection site with an alcohol swab, and let it dry completely. Inject at the same time each day as directed by your fertility clinic, rotating the site slightly with each dose. Your clinic will provide hands-on instruction before you begin self-administering. If you are uncertain about any step of the process, contact your care team before proceeding rather than attempting to inject independently.
Most patients take ganirelix for approximately 4 to 6 days before egg retrieval, though the exact duration depends on your individual follicle development and your clinic's protocol. Ganirelix is typically started on stimulation day 5 or 6 — or when the lead follicle reaches approximately 13-14 mm — and is continued daily until the trigger shot is administered. Your fertility specialist will confirm your specific start and stop dates based on serial ultrasound and hormone monitoring throughout your cycle. Never start or stop ganirelix independently of clinic guidance.
Ganirelix suppresses the LH surge within hours of the first injection and maintains that suppression for as long as daily injections continue. Once ganirelix is discontinued after the trigger injection, suppression reverses rapidly — the drug has a short duration of action, typically clearing within one to two days. This rapid reversibility is one of its practical advantages over GnRH agonist protocols, which require a longer washout period before ovulation can proceed. The suppression window is calibrated entirely by the daily injection schedule your fertility clinic prescribes.
Yes — ganirelix prefilled syringes should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. Do not freeze ganirelix, as freezing damages the medication. Once removed from the refrigerator, ganirelix can be kept at room temperature below 25°C (77°F) for a limited period — check your specific product labeling for the precise room temperature storage window. Inspect the solution before each injection — it should be clear and colorless. Do not use a syringe that appears cloudy, discolored, or contains particles.
Contact your fertility clinic immediately if you miss a scheduled ganirelix injection — do not make an independent decision about whether or when to administer the missed dose. A missed dose creates a window in which a premature LH surge could occur, potentially compromising your cycle timing. Your clinic will advise on the safest course of action based on your stimulation status, your most recent ultrasound findings, and your hormone levels. Never double the dose on the following day without explicit clinic instruction.
Uses & Mechanism of Action
Transvaginal ultrasound and blood hormone testing are scheduled throughout your stimulation cycle and are an essential part of safe ganirelix use. Ultrasound tracks follicle growth and determines when ganirelix should be started and when follicles are mature enough for retrieval. Blood estradiol and LH levels confirm that stimulation is progressing appropriately and that premature ovulation has not occurred. This monitoring drives all dosing decisions — including trigger shot timing and retrieval scheduling — making attendance at every clinic appointment a critical part of your cycle.
Ganirelix acetate is FDA-approved for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology program, most commonly IVF. It is used specifically within GnRH antagonist protocols and is not a standalone fertility treatment — it works alongside gonadotropin stimulation medications as part of a coordinated cycle. Without an agent to prevent premature ovulation, rising estrogen levels from multiple developing follicles can trigger an unintended LH surge before the fertility team is ready to retrieve eggs.
Ganirelix acetate is a synthetic decapeptide — a manufactured compound of ten amino acids — classified as a gonadotropin-releasing hormone (GnRH) antagonist. It belongs to the same drug class as cetrorelix (Cetrotide). Ganirelix is supplied as a prefilled, ready-to-inject subcutaneous syringe requiring no reconstitution before use. It was the first GnRH antagonist approved by the FDA for IVF protocols and is one of the most widely used fertility medications globally for preventing premature ovulation during controlled ovarian stimulation.
In IVF, ganirelix prevents a premature LH surge from occurring during the late phase of ovarian stimulation, preserving the fertility team's control over egg retrieval timing. It is introduced mid-stimulation — after follicles have already begun developing under gonadotropin therapy — and maintained daily until the trigger injection is given. Its role is not to stimulate follicle growth or improve egg quality but specifically to hold the LH surge in check so that retrieval can be scheduled at the optimal moment for egg maturity.
Ganirelix works by competitively and reversibly binding to GnRH receptors on the anterior pituitary gland, occupying them without activating them. This blocks the pituitary's response to naturally produced gonadotropin-releasing hormone, rapidly suppressing LH secretion within hours of the first dose. Unlike GnRH agonists, which cause an initial hormone flare before achieving suppression, ganirelix produces immediate suppression with no flare — allowing it to be introduced mid-stimulation rather than requiring weeks of pre-treatment. Suppression is maintained as long as daily injections continue and reverses quickly once they stop.
In a GnRH antagonist IVF protocol, ovarian stimulation begins with daily gonadotropin injections on day 2 or 3 of the menstrual cycle. Ganirelix is added several days later — once follicles reach a target size — running alongside the gonadotropins until the lead follicles are mature. A trigger injection then completes final egg maturation, ganirelix is stopped, and retrieval occurs approximately 34 to 36 hours later. The antagonist protocol is now the most widely used IVF stimulation approach globally due to its shorter duration, scheduling flexibility, and lower OHSS risk compared to agonist protocols.
Side Effects & Safety
The most commonly reported side effects of ganirelix include injection site reactions — redness, bruising, itching, and mild swelling — which are generally transient and manageable with proper injection technique and site rotation. Headache and nausea are also reported. Abdominal discomfort and bloating during stimulation are more attributable to the gonadotropin component of the protocol than to ganirelix specifically. Serious allergic reactions including anaphylaxis have been reported rarely, and any signs of a systemic allergic response after injection require immediate medical attention.
Ovarian hyperstimulation syndrome (OHSS) is a complication of controlled ovarian stimulation in which the ovaries overrespond to gonadotropin medications, becoming enlarged and releasing fluid into the abdominal cavity. Symptoms range from mild bloating and nausea to severe fluid accumulation, abdominal pain, and decreased urine output. One practical advantage of GnRH antagonist protocols using ganirelix is that they permit the use of a GnRH agonist trigger instead of hCG in high-risk patients, which substantially reduces severe OHSS risk. Your fertility clinic will monitor your ovarian response closely and advise on OHSS risk management specific to your cycle.
Ganirelix has an established safety profile within IVF protocols, supported by over two decades of clinical use and large clinical trials. It is well tolerated by most patients, with the most common adverse effects being local injection site reactions. Ganirelix is contraindicated during pregnancy and must not be used after conception. It is also contraindicated in patients with known hypersensitivity to ganirelix, mannitol, GnRH, or other GnRH analogs. Patients with a history of severe allergic reactions should discuss this with their reproductive endocrinologist before starting ganirelix.
Available clinical evidence does not suggest that ganirelix directly impairs egg quality. GnRH antagonist protocols have been compared extensively to agonist protocols in clinical trials, with egg quality, fertilization rates, and pregnancy outcomes broadly comparable between the two approaches. Factors that most significantly influence egg quality — including age, ovarian reserve, and individual response to stimulation — are independent of which suppression agent is used. Your reproductive endocrinologist will select the protocol best suited to your ovarian reserve and response history.
Ganirelix itself does not cause cycle failure — its role is to prevent premature ovulation, and when used as directed it performs this reliably. IVF outcomes depend on many factors beyond suppression, including egg and sperm quality, embryo development, and endometrial receptivity. A missed or mistimed ganirelix dose that allows a premature LH surge can compromise a cycle by triggering ovulation before retrieval — which is why daily adherence and immediate clinic contact if a dose is missed are emphasized throughout treatment.
Interactions & Contraindications
Ganirelix is contraindicated in women who are pregnant — treatment must be stopped immediately if pregnancy is confirmed. It is contraindicated in patients with known hypersensitivity to ganirelix acetate, mannitol, GnRH, or any GnRH analog. Women with severe renal or hepatic impairment have not been adequately studied, and ganirelix should be used with caution in these populations under specialist guidance. Ganirelix is not indicated for use in postmenopausal women or in men. Your reproductive endocrinologist will review your medical history and allergy profile before incorporating ganirelix into your protocol.
Ganirelix is used alongside gonadotropin medications — including recombinant FSH products and LH-containing products — as a standard component of antagonist protocols, and these combinations are well characterized with no clinically significant pharmacokinetic interactions. Formal drug interaction studies with non-fertility medications have not been conducted. If you are taking any prescription medications, supplements, or herbal products alongside your IVF protocol, disclose all of these to your fertility clinic before your cycle begins so that any potential concerns can be assessed in advance.
Women with polycystic ovary syndrome can use ganirelix, and GnRH antagonist protocols are often preferred in this population due to the OHSS risk reduction they offer. Women with PCOS are at significantly elevated OHSS risk given their high antral follicle counts and exaggerated ovarian response to stimulation. Antagonist protocols with ganirelix allow use of a GnRH agonist trigger instead of hCG, substantially lowering severe OHSS risk. Your reproductive endocrinologist will tailor the stimulation approach and trigger strategy to manage OHSS risk, specifically if PCOS is a factor in your treatment.
Starting ganirelix before follicles have reached the appropriate size can suppress FSH and LH to a degree that slows follicle development, potentially reducing the number of eggs available for retrieval. Timing of ganirelix initiation is determined by monitoring — specifically follicle size on ultrasound and estradiol levels — rather than by a fixed calendar day. Beginning injections before your clinic advises is not recommended. If you are uncertain about your start date, contact your clinic before injecting rather than proceeding independently.
Generic & Alternatives
The generic name is ganirelix acetate, and generic ganirelix acetate injection is available in the United States in prefilled syringes bioequivalent to the original brand-name Antagon. Generic ganirelix acetate contains the same active compound at the same concentration and is expected to provide equivalent LH suppression within IVF protocols. Fertility medications including ganirelix are typically dispensed through specialty fertility pharmacies rather than standard retail pharmacies. Your fertility clinic or pharmacy coordinator can advise on sourcing and current availability.
The primary alternative within the GnRH antagonist class is cetrorelix acetate (Cetrotide), which acts via the same mechanism and is used in the same way as other antagonists. The choice between ganirelix and cetrorelix is generally guided by availability and clinic preference rather than meaningful clinical differences in efficacy or safety. GnRH agonist protocols — using medications such as leuprolide acetate — represent the other major category of ovulation suppression in IVF and may be preferred in specific clinical scenarios such as poor ovarian response or endometriosis-related considerations.
GnRH agonists such as leuprolide initially cause a surge in LH and FSH before eventually desensitizing pituitary function — a flare effect requiring two to four weeks of pre-treatment before stimulation can begin. Ganirelix produces immediate competitive receptor blockade with no initial hormone flare, allowing it to be introduced mid-stimulation and making antagonist protocols significantly shorter and more flexible. Antagonist protocols also carry lower OHSS risk in high-responders when a GnRH agonist trigger is used — an option not available in standard agonist cycles where the pituitary remains suppressed throughout.
Ganirelix is FDA-approved specifically for preventing premature LH surges during controlled ovarian hyperstimulation in ART programs and does not have approved indications outside this context in the United States. GnRH antagonists as a class have been studied for conditions including endometriosis, uterine fibroids, and prostate cancer. Still, the agents used clinically for these indications — such as elagolix and degarelix — are different compounds with different pharmacological profiles. Your reproductive endocrinologist can clarify whether ganirelix is appropriate for your specific fertility treatment plan.
Disclaimer
The information provided on this page is for general informational purposes only and is not intended as medical advice. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication regimen. While Invictus strives to provide accurate and up-to-date information, individual health conditions and circumstances vary. The prices, availability, and descriptions of all medications on this page are subject to change.
Your Prescription
Ready to Fill
